Novel Immunotherapy Shows Early Efficacy in Uveal Melanoma

Soucre: OncLive, May 2018

IMCgp100, a novel immune-based treatment, demonstrated a 1-year survival rate of 73% (95% CI, 46%-88%) for patients with heavily pretreated, advanced uveal melanoma, which is nearly double the historical expectations for patients with the disease, according to lead investigator Richard D. Carvajal, MD.
At a median follow-up of 12.8 months, the median overall survival had not yet been reached in the phase I study. The objective response rate with IMCgp100 was 11% among (90% CI, 2%-30%), with 5 additional patients (26%) showing signs of stable disease with minor responses (?10% reduction in target lesions). The median progression- free survival (PFS) with the treatment was 24.3 weeks, and 62% of patients remained alive and progression free at 1 year (Table).
“Advanced uveal melanoma has a 1-year overall survival rate of approximately 40%, and no cytotoxic, targeted, or immunological therapy has been previously identified to meaningfully improve outcomes,” Carvajal said at the Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting, where he presented the data. Carvajal is director of Experimental Therapeutics and the Melanoma Service at Columbia University Medical Center in New York, New York.